Special lssues

Identification of Novel Cancer Biomarkers in the Era of Precision Medicine

Submission Deadline: 30 June 2022 (closed)

Guest Editors

Jianxin Shi
Shanghai Jiao Tong University, Shanghai, China

Chang Gu
Tongji University School of Medicine, Shanghai, China.
E-mail: guchang0107@126.com

Jun Yang
Shanghai Jiao Tong University, Shanghai, China.
E-mail: jyang_sch@163.com

Yue Wang
Department of Pharmacology and Toxicology, Wright State University, Fairborn, OH, 45435, USA.
E-mail: wangyue41428@gmail.com


Based on the Precision Medicine Initiative, precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person." This innovative approach will allow doctors and researchers to predict more accurately which prevention and treatment strategies for specific cancer will work in which subgroups of patients. In the recent decades, tremendous developments have been seen in high throughput genomic and molecular profiling and image-based technologies, which result in new discoveries of diverse potential cancer biomarkers that will promisingly provide a deeper understanding of the molecular processes of cancers. Therefore, biomarkers will serve as powerful tools to precisely identify high-risk individual patients, improve diagnostic accuracy, develop tailored follow-up policies, recognize the sensitivity to targeted therapy or immunotherapy, and predict the prognosis determination.


However, some barriers still exist in identification of novel cancer biomarkers in the era of precision medicine, limiting the reach to all potential patients: (1) the diversity in biomedical research, which restricts the general applicability of gene-based prevention, monitoring and treatment strategies, especially in oncology; (2) the integration of clinical and biological information and its interpretation. Clinicians have obstacles in interpreting the biomarkers well, especially molecular genetic information, from unfamiliar laboratories, and it is an urgent need to make a clear standardization.


The goal of this Special Issue is to summarize new advances in both existing and novel predictive and prognostic molecular and imaging biomarkers for cancers in the era of precision medicine, especially in risk prediction, screening, diagnosis, and prognosis. Original research, commentaries, perspectives, and reviews are all welcome.


Potential topics include but are not limited to the following:

1. Genetic and epigenetic changes that might be used as relevant biomarkers

2. Imaging markers for personalized cancer prevention, monitoring and treatment

3. Bioinformatics analysis of the prevention, treatment, and prognosis of a variety of cancers

4. Define suitable biomarkers for proper clinical trials

5. The use of biomarkers for the cancer patient stratification, the follow-up and to predict therapeutic response

6. Body fluid biomarkers for individualized cancer prognosis, treatment, and prognosis

7. Mechanistic researches relating to specific biomarkers

8. Advanced techniques to identify or measure biomarkers

9. Identification and validation novel biomarkers which help clinical decision-making

10. Predictive and prognostic biomarkers in targeted and immunotherapy


Cancer Biomarkers, Precision Medicine, cancer treatment, cancer patient stratification, individualized cancer prognosis

Share Link